BNP Paribas Financial Markets Has $4.21 Million Stock Holdings in Twist Bioscience Co. (NASDAQ:TWST)

BNP Paribas Financial Markets grew its holdings in Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 138.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 90,527 shares of the company's stock after purchasing an additional 52,495 shares during the period. BNP Paribas Financial Markets owned about 0.15% of Twist Bioscience worth $4,207,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of TWST. Arizona State Retirement System raised its stake in shares of Twist Bioscience by 1.3% in the fourth quarter. Arizona State Retirement System now owns 16,985 shares of the company's stock worth $789,000 after buying an additional 219 shares during the period. Van ECK Associates Corp increased its stake in shares of Twist Bioscience by 56.4% in the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company's stock worth $34,000 after purchasing an additional 267 shares in the last quarter. Hillsdale Investment Management Inc. raised its position in shares of Twist Bioscience by 0.4% during the 4th quarter. Hillsdale Investment Management Inc. now owns 78,000 shares of the company's stock valued at $3,625,000 after purchasing an additional 300 shares during the period. Summit Investment Advisors Inc. lifted its stake in shares of Twist Bioscience by 7.8% during the 4th quarter. Summit Investment Advisors Inc. now owns 6,098 shares of the company's stock valued at $283,000 after buying an additional 443 shares in the last quarter. Finally, US Bancorp DE increased its stake in Twist Bioscience by 72.0% in the 4th quarter. US Bancorp DE now owns 1,436 shares of the company's stock worth $67,000 after buying an additional 601 shares in the last quarter.

Insider Transactions at Twist Bioscience

In other news, COO Patrick John Finn sold 2,800 shares of the firm's stock in a transaction on Monday, May 5th. The shares were sold at an average price of $37.65, for a total value of $105,420.00. Following the transaction, the chief operating officer now owns 262,660 shares of the company's stock, valued at approximately $9,889,149. This trade represents a 1.05% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Emily M. Leproust sold 5,042 shares of the firm's stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $37.65, for a total value of $189,831.30. Following the sale, the chief executive officer now owns 655,432 shares of the company's stock, valued at $24,677,014.80. This represents a 0.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 18,991 shares of company stock valued at $742,654. 3.01% of the stock is currently owned by company insiders.

Twist Bioscience Stock Performance

Shares of NASDAQ:TWST traded up $0.01 during trading on Tuesday, hitting $30.40. The stock had a trading volume of 91,339 shares, compared to its average volume of 969,007. Twist Bioscience Co. has a 12-month low of $28.46 and a 12-month high of $60.90. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $1.82 billion, a price-to-earnings ratio of -8.99 and a beta of 2.54. The stock has a 50-day simple moving average of $37.64 and a two-hundred day simple moving average of $43.24.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.10). Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The company had revenue of $92.79 million during the quarter, compared to analyst estimates of $92.00 million. On average, equities research analysts expect that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on TWST. Robert W. Baird dropped their price objective on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. Barclays cut their price objective on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a report on Thursday, April 10th. JPMorgan Chase & Co. dropped their target price on shares of Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. Scotiabank reiterated an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Finally, Guggenheim restated a "buy" rating and set a $50.00 price objective on shares of Twist Bioscience in a research report on Tuesday, May 6th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, Twist Bioscience presently has a consensus rating of "Moderate Buy" and an average target price of $50.40.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.